ZNTL advances pivotal Azenosertib ovarian cancer trials with FDA support
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, citing a robust safety profile and a validated biomarker strategy. The company says FDA alignment is strong and highlights a differentiated oral option.